RFL Rafael Holdings, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1713863 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.7%
TTM net income YoY-58.3%
TTM EPS YoY44.2%
Revenue 3-yr CAGR46.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,821.2%
Net margin-3,390.7%
FCF margin—
EBITDA margin-3,797.8%
Returns
ROE-36.9%
ROA-30.1%
ROIC (approx.)-61.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio2.35x
Interest coverage-100.29x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-07-31 | FY20252025-07-31 |
|---|---|---|
| Income statement | ||
| Revenue | $874,000 | $917,000 |
| R&D expense | $24.33M | $12.82M |
| SG&A expense | $9.70M | $13.78M |
| Operating income | -$33.41M | -$29.16M |
| Interest expense | $333,000 | $658,000 |
| Pretax income | -$27.97M | -$33.20M |
| Income tax | -$13,000 | -$2.55M |
| Net income | -$29.64M | -$30.52M |
| EBITDA | -$33.20M | -$28.87M |
| EPS (basic) | -0.58 | -1.04 |
| EPS (diluted) | -0.58 | -1.04 |
| Weighted avg. shares (diluted) | 51.39M | 29.42M |
| Balance sheet | ||
| Cash & equivalents | $22.10M | $52.77M |
| Receivables | $444,000 | $627,000 |
| Inventory | $377,000 | $281,000 |
| Current assets | $25.82M | $56.71M |
| PP&E, net | $1.50M | $1.60M |
| Goodwill | $19.94M | $19.94M |
| Intangibles | $863,000 | $994,000 |
| Total assets | $83.06M | $114.11M |
| Current liabilities | $10.99M | $11.60M |
| Total liabilities | $11.09M | $15.74M |
| Shareholders' equity | $66.31M | $94.39M |
| Cash flow statement | ||
| Operating cash flow | -$29.99M | -$18.92M |
| Capital expenditure | $3,000 | $4,000 |
| Free cash flow | -$29.99M | -$18.93M |
| Investing cash flow | -$676,000 | $44.03M |
| Financing cash flow | -$116,000 | $24.83M |
| Depreciation & amortization | $204,000 | $288,000 |
| Stock-based compensation | $1.39M | $2.12M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.